The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Amebiasis is an infection of the intestine caused by a parasite Entamoeba Histolytica. Symptoms of this disease include loose stool, abdominal cramping, and stomach pain.
The global Amebiasis market was valued at US$ 875 million in 2023 and is anticipated to reach US$ 1323.9 million by 2030, witnessing a CAGR of 6.1% during the forecast period 2024-2030.
The amebiasis drugs market is driven by the high burden of amebiasis infections, caused by the parasite Entamoeba histolytica, especially in developing regions with poor sanitation and healthcare facilities. Amebiasis can lead to severe gastrointestinal symptoms and potentially life-threatening complications. The increasing prevalence and severity of the disease have contributed to the demand for effective drugs to treat and manage amebiasis. Additionally, advancements in medical research and drug development have led to the introduction of new and improved therapies for better patient outcomes. However, challenges include the need for early diagnosis and proper management to prevent complications, potential drug resistance, and limited access to healthcare in some regions. Overcoming these challenges through increased awareness, affordable treatment options, and improved healthcare infrastructure will be crucial for the sustained growth of the amebiasis drugs market.
This report aims to provide a comprehensive presentation of the global market for Amebiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amebiasis.
Report Scope
The Amebiasis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amebiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amebiasis companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr. Reddy’s Laboratories
Mission Pharmacal
Aceto Corporation
Mylan Pharmaceuticals
Impax Laboratories
Pfizer
Sanofi
Lupin Pharmaceuticals
Glenmark Pharmaceuticals
Sun Pharmaceutical
Heritage Pharmaceuticals
Segment by Type
Metronidazole
Paromomycin
Tinidazole
Other
Segment by Application
Hospital
Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amebiasis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Amebiasis is an infection of the intestine caused by a parasite Entamoeba Histolytica. Symptoms of this disease include loose stool, abdominal cramping, and stomach pain.
The global Amebiasis market was valued at US$ 875 million in 2023 and is anticipated to reach US$ 1323.9 million by 2030, witnessing a CAGR of 6.1% during the forecast period 2024-2030.
The amebiasis drugs market is driven by the high burden of amebiasis infections, caused by the parasite Entamoeba histolytica, especially in developing regions with poor sanitation and healthcare facilities. Amebiasis can lead to severe gastrointestinal symptoms and potentially life-threatening complications. The increasing prevalence and severity of the disease have contributed to the demand for effective drugs to treat and manage amebiasis. Additionally, advancements in medical research and drug development have led to the introduction of new and improved therapies for better patient outcomes. However, challenges include the need for early diagnosis and proper management to prevent complications, potential drug resistance, and limited access to healthcare in some regions. Overcoming these challenges through increased awareness, affordable treatment options, and improved healthcare infrastructure will be crucial for the sustained growth of the amebiasis drugs market.
This report aims to provide a comprehensive presentation of the global market for Amebiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amebiasis.
Report Scope
The Amebiasis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amebiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amebiasis companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr. Reddy’s Laboratories
Mission Pharmacal
Aceto Corporation
Mylan Pharmaceuticals
Impax Laboratories
Pfizer
Sanofi
Lupin Pharmaceuticals
Glenmark Pharmaceuticals
Sun Pharmaceutical
Heritage Pharmaceuticals
Segment by Type
Metronidazole
Paromomycin
Tinidazole
Other
Segment by Application
Hospital
Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amebiasis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Amebiasis Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Metronidazole
1.2.3 Paromomycin
1.2.4 Tinidazole
1.2.5 Other
1.3 Market by Application
1.3.1 Global Amebiasis Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Amebiasis Market Perspective (2019-2030)
2.2 Amebiasis Growth Trends by Region
2.2.1 Global Amebiasis Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Amebiasis Historic Market Size by Region (2019-2024)
2.2.3 Amebiasis Forecasted Market Size by Region (2025-2030)
2.3 Amebiasis Market Dynamics
2.3.1 Amebiasis Industry Trends
2.3.2 Amebiasis Market Drivers
2.3.3 Amebiasis Market Challenges
2.3.4 Amebiasis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Amebiasis Players by Revenue
3.1.1 Global Top Amebiasis Players by Revenue (2019-2024)
3.1.2 Global Amebiasis Revenue Market Share by Players (2019-2024)
3.2 Global Amebiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Amebiasis Revenue
3.4 Global Amebiasis Market Concentration Ratio
3.4.1 Global Amebiasis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Amebiasis Revenue in 2023
3.5 Amebiasis Key Players Head office and Area Served
3.6 Key Players Amebiasis Product Solution and Service
3.7 Date of Enter into Amebiasis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Amebiasis Breakdown Data by Type
4.1 Global Amebiasis Historic Market Size by Type (2019-2024)
4.2 Global Amebiasis Forecasted Market Size by Type (2025-2030)
5 Amebiasis Breakdown Data by Application
5.1 Global Amebiasis Historic Market Size by Application (2019-2024)
5.2 Global Amebiasis Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Amebiasis Market Size (2019-2030)
6.2 North America Amebiasis Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Amebiasis Market Size by Country (2019-2024)
6.4 North America Amebiasis Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Amebiasis Market Size (2019-2030)
7.2 Europe Amebiasis Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Amebiasis Market Size by Country (2019-2024)
7.4 Europe Amebiasis Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Amebiasis Market Size (2019-2030)
8.2 Asia-Pacific Amebiasis Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Amebiasis Market Size by Region (2019-2024)
8.4 Asia-Pacific Amebiasis Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Amebiasis Market Size (2019-2030)
9.2 Latin America Amebiasis Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Amebiasis Market Size by Country (2019-2024)
9.4 Latin America Amebiasis Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Amebiasis Market Size (2019-2030)
10.2 Middle East & Africa Amebiasis Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Amebiasis Market Size by Country (2019-2024)
10.4 Middle East & Africa Amebiasis Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dr. Reddy’s Laboratories
11.1.1 Dr. Reddy’s Laboratories Company Detail
11.1.2 Dr. Reddy’s Laboratories Business Overview
11.1.3 Dr. Reddy’s Laboratories Amebiasis Introduction
11.1.4 Dr. Reddy’s Laboratories Revenue in Amebiasis Business (2019-2024)
11.1.5 Dr. Reddy’s Laboratories Recent Development
11.2 Mission Pharmacal
11.2.1 Mission Pharmacal Company Detail
11.2.2 Mission Pharmacal Business Overview
11.2.3 Mission Pharmacal Amebiasis Introduction
11.2.4 Mission Pharmacal Revenue in Amebiasis Business (2019-2024)
11.2.5 Mission Pharmacal Recent Development
11.3 Aceto Corporation
11.3.1 Aceto Corporation Company Detail
11.3.2 Aceto Corporation Business Overview
11.3.3 Aceto Corporation Amebiasis Introduction
11.3.4 Aceto Corporation Revenue in Amebiasis Business (2019-2024)
11.3.5 Aceto Corporation Recent Development
11.4 Mylan Pharmaceuticals
11.4.1 Mylan Pharmaceuticals Company Detail
11.4.2 Mylan Pharmaceuticals Business Overview
11.4.3 Mylan Pharmaceuticals Amebiasis Introduction
11.4.4 Mylan Pharmaceuticals Revenue in Amebiasis Business (2019-2024)
11.4.5 Mylan Pharmaceuticals Recent Development
11.5 Impax Laboratories
11.5.1 Impax Laboratories Company Detail
11.5.2 Impax Laboratories Business Overview
11.5.3 Impax Laboratories Amebiasis Introduction
11.5.4 Impax Laboratories Revenue in Amebiasis Business (2019-2024)
11.5.5 Impax Laboratories Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Amebiasis Introduction
11.6.4 Pfizer Revenue in Amebiasis Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Amebiasis Introduction
11.7.4 Sanofi Revenue in Amebiasis Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 Lupin Pharmaceuticals
11.8.1 Lupin Pharmaceuticals Company Detail
11.8.2 Lupin Pharmaceuticals Business Overview
11.8.3 Lupin Pharmaceuticals Amebiasis Introduction
11.8.4 Lupin Pharmaceuticals Revenue in Amebiasis Business (2019-2024)
11.8.5 Lupin Pharmaceuticals Recent Development
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Detail
11.9.2 Glenmark Pharmaceuticals Business Overview
11.9.3 Glenmark Pharmaceuticals Amebiasis Introduction
11.9.4 Glenmark Pharmaceuticals Revenue in Amebiasis Business (2019-2024)
11.9.5 Glenmark Pharmaceuticals Recent Development
11.10 Sun Pharmaceutical
11.10.1 Sun Pharmaceutical Company Detail
11.10.2 Sun Pharmaceutical Business Overview
11.10.3 Sun Pharmaceutical Amebiasis Introduction
11.10.4 Sun Pharmaceutical Revenue in Amebiasis Business (2019-2024)
11.10.5 Sun Pharmaceutical Recent Development
11.11 Heritage Pharmaceuticals
11.11.1 Heritage Pharmaceuticals Company Detail
11.11.2 Heritage Pharmaceuticals Business Overview
11.11.3 Heritage Pharmaceuticals Amebiasis Introduction
11.11.4 Heritage Pharmaceuticals Revenue in Amebiasis Business (2019-2024)
11.11.5 Heritage Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
